Neuropathix, Inc.
NPTX
Other OTC0.00
USD
- -
- -
CIK
0001615999
ISIN
US64132Q1094
CUSIP
64132Q109
Return %
Stock
S&P500
1Y
-98.50
19.01
3Y
-99.97
65.48
5Y
-99.97
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Dean Petkanas
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3805 Old Easton Road Doylestown PA United States of America 18902
- IPO Date
- Dec 5, 2019
- CIK
- 0001615999
- Website
- neuropathix.com
- Similar Companies
- Business
- Neuropathix, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutics for neurological and inflammatory diseases. The company's core products and services include proprietary drug candidates designed to address chronic pain, inflammation, and underlying disease processes in neuropathic conditions; its leading pipeline features NP-120 (iflaminibs), a patented therapeutic targeting neuropathic pain and neuro-inflammation. Neuropathix operates primarily in the pharmaceutical and biotechnology industry, providing its products and services to healthcare providers, pharmaceutical partners, and research institutions across the United States and internationally. Founded in 2008, the company is headquartered in Miami, Florida. Recent strategic developments include the company advancing its clinical programs, particularly the initiation and progression of late-stage trials for NP-120, as well as expanding its research collaborations and partnerships to enhance its drug development capabilities. In the past 1-2 years, Neuropathix has strengthened its operational focus on neurological conditions, including neuropathic pain and Alzheimer's disease-related targets, reflecting a strategic shift towards specialty therapeutics with significant unmet medical needs. The company also continues to explore commercialization opportunities and potential market expansion for its lead compounds, positioning itself as a promising innovator in the neurotherapeutics sector. Neuropathix serves the pharmaceutical and healthcare industry segments targeting patients with neuropathic and inflammatory disorders. Its geographic footprint includes the United States with ongoing research and clinical trials that engage global partners. The company functions as a standalone entity with a focus on novel drug development, leveraging proprietary technology platforms. Overall, Neuropathix, Inc. offers a portfolio of advanced therapeutic candidates for neurological diseases, supported by strategic clinical development initiatives and partnerships, and is based in Miami, Florida, where it was founded in 2008.
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead